mavorixafor · X4 Pharms · NDA 218709
Xolremdi
Earliest generic entry, as listed
11 Dec 2038
Blocked by patent: US 10548889, US 11045461, US 12115156.
Listed patents · 6 unexpired
| Patent | Claims | Expires |
|---|---|---|
| US 10548889 | product | 11 Dec 2038 |
| US 11045461 | product | 11 Dec 2038 |
| US 12115156 | product | 11 Dec 2038 |
| US 10610527 | use U-3932 | 22 Dec 2036 |
| US 11219621 | use U-3932 | 22 Dec 2036 |
| US 10953003 | product | 14 Dec 2036 |
Exclusivities · 2 unexpired
| ODE-480 | orphan drug (7 years) | 26 Apr 2031 |
| NCE | new chemical entity (5 years) | 26 Apr 2029 |
Paragraph IV certifications · 0
No Paragraph IV certification listed by FDA for this drug.
The list shows that a generic applicant certified to FDA that a listed patent is invalid or not infringed. It does not show litigation, settlements or launch timing.
Event history
No events yet. The first ingestion only records products entering their 12-month window; changes appear from the next Orange Book update.
Products covered · 1
| NDA · product | Form | Strength | Listed expiry |
|---|---|---|---|
| 218709 · 001 · RLD | capsule, oral | 100MG | 11 Dec 2038 |